Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of study is to compare the efficacy and safety of ONO-4538 in combination with
carboplatin, paclitaxel, and bevacizumab (ONO-4538 group) to placebo in combination with
carboplatin, paclitaxel, and bevacizumab (placebo group) in chemotherapy-naïve subjects with
stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical
radiation in a multicenter, randomized, double-blind study.